嗜铬粒蛋白A与去势抵抗性前列腺癌的相关性研究

Study on correlation between chromogranin A and castration resistant prostate cancer

目的探讨嗜铬粒蛋白A(Cg A)与去势抵抗性前列腺癌(CRPC)的相关性。方法选取2011年1月-2012年8月于川北医学院附属医院经前列腺穿刺活检证实为前列腺癌的75例组织标本,以免疫组织化学方法检测Cg A在穿刺标本中的表达情况,分析Cg A表达率与前列腺癌各临床病理参数的关系,并比较Cg A表达阳性组与阴性组发展至CRPC的差异。结果 75例前列腺癌穿刺标本中,36例Cg A表达阳性(48.0%)。Cg A的表达与PSA水平、Gleason评分以及临床分期有关(P<0.05),Cg A阳性组发展至CRPC的发生率明显高于Cg A阴性组(P<0.01)。结论 Cg A与CRPC的发生密切相关。监测Cg A的表达情况,对前列腺癌的内分泌治疗效果的预测可能有一定的临床指导意义。

Objective To investigate the relationship between chromogranin A （CgA） and castration resistant prostate cancer （CRPC）. Methods A total of 75 cases of prostate cancer specimens were stained by immunohistochemistry, and the relationship between CgA expression and CRPC were analyzed. Results Among 75 cases, 36 cases were CgA positive （48.0%）. CgA expression was significantly associated with Gleason score, serum prostate specific antigen and disease stage （P 〈 0.05）. The incidence of CRPC in CgA positive group was significantly higher than that in CgA negative group （P 〈 0.05）. Conclusions The results suggest that CgA is associated with CRPC. Monitoring the expression of CgA may be helpful for the treatment of prostate cancer patients who receive endocrine therapy.